Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Anjali Nobile

Neurology Tamarac, FL Medical Doctor

NPI 1871869792 CMS profile 1382622

7481 W Oakland Park Blvd, Ste 100, Tamarac, FL 33319

Open in the dashboard

General payments

$5,422

152 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Anjali Nobile of Tamarac, FL is reported in the CMS Open Payments database as having received $5,422 across 152 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 67th percentile of Neurology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $91 4
2024 General $154 6
2023 General $136 5
2022 General $2,666 20
2021 General $644 24
2020 General $291 15
2019 General $1,438 78

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Anjali Nobile
  • Neurology median
  • Middle half of Neurology
  • National median

In program year 2025, general payments to Anjali Nobile were reported at $91. Among 11,022 Neurology profiles paid that year, the median was $457 and the middle half received between $118 and $2,344.

Show as a table
Year Anjali Nobile Neurology median Middle half National median
2019 $1,438 $474 $118–$2,177 $163
2020 $291 $367 $82–$2,309 $114
2021 $644 $438 $104–$2,547 $132
2022 $2,666 $442 $103–$2,388 $149
2023 $136 $464 $119–$2,312 $160
2024 $154 $468 $119–$2,323 $164
2025 $91 $457 $118–$2,344 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Abbott Laboratories $2,954 40 payments
  2. Otsuka America Pharmaceutical, Inc. $540 21 payments
  3. Teva Pharmaceuticals USA, Inc. $480 14 payments
  4. Allergan Inc. $379 28 payments
  5. Lundbeck LLC $255 13 payments
  6. Vanda Pharmaceuticals Inc. $227 11 payments
  7. AbbVie, Inc. $116 5 payments
  8. GRT US Holding, Inc. $106 1 payment
  9. Neurocrine Biosciences, Inc. $83 5 payments
  10. Sunovion Pharmaceuticals Inc. $82 4 payments
  11. Other $198 10 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $3,699 145 payments
  2. Travel and Lodging $1,647 6 payments
  3. Education $76 1 payment
Products named General payments · program years 2019–2025
  1. PROCLAIM Neuromodulation $1,599 15 payments
  2. PROCLAIM Neuromodulation $835 3 payments
  3. Proclaim IPG $521 22 payments
  4. REXULTI Psychiatry $357 9 payments
  5. AUSTEDO $345 10 payments
  6. VRAYLAR $261 26 payments
  7. HETLIOZ $227 11 payments
  8. FANAPT $227 11 payments
  9. ABILIFY MAINTENA $183 12 payments
  10. REXULTI Psychiatry $148 8 payments
  11. Other $971 39 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 29 drugs

Part D claims

699

Median for Neurology: 833

Drug cost

$13,833

Median for Neurology: $202,670

Branded share of claims

15.9%

Median for Neurology: 25.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Tetrabenazine Generic 11 $2,598
Gabapentin Generic 119 $1,612
Carbamazepine Er Carbamazepine Brand 25 $1,225
Lacosamide Generic 13 $1,149
Divalproex Sodium Generic 23 $931
Diclofenac Sodium Generic 28 $853
Quetiapine Fumarate Er Quetiapine Fumarate Brand 12 $812
Baclofen Generic 44 $768
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 28 $604
Levetiracetam Generic 17 $572

The 10 drugs with the highest cost, of 29 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,695 Part D prescribers listed as Neurology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 21 billing codes

Paid by Medicare

$49,416

Medicare's payments for the services billed

Medicare patients

50

Average age 61

Services billed

499

32 women, 18 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 56%
Depression 50%
Arthritis 50%
Diabetes 36%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 6 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
QULIPTA
  • AbbVie, Inc. $39
$39 — —
Austedo XR
  • Teva Pharmaceuticals USA, Inc. $31
$31 — —
BOTOX
  • AbbVie, Inc. $25
$25 — —
Qelbree
  • Supernus Pharmaceuticals, Inc. $23
$23 — —
GIVLAARI
  • Alnylam Pharmaceuticals Inc. $22
$22 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 6 in the dashboard with a free account

Records

152 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurology in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record